drugset
drugset / Trial / NCT03025958

Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

NCT03025958 ↗

Phase 2 Completed 30 enrolled Zhejiang Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Timeline

Start
2017-03-13
Primary completion
2018-11-12
Completion
2023-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Nimotuzumab Monoclonal antibody 200 mg —

Indications

nasopharyngeal carcinoma